Introduction to the Replimune Class Action Lawsuit

Replimune Class Action Lawsuit: A securities class action lawsuit is pending against Replimune Group, Inc. (NASDAQ: REPL) for investors who purchased securities between October 20, 2025, and April 10, 2026. The case, Toor v. Replimune Group, Inc., No. 26-cv-13612, is in the U.S. District Court for the District of Massachusetts, with a lead plaintiff deadline of October 5, 2026.

Case Details & Allegations 

  • The Class Period: October 20, 2025 through April 10, 2026.
  • Undisclosed Issues: The company allegedly failed to disclose that it did not adequately address prior FDA study design concerns, relied on an early unplanned analysis from a tiny patient sample (40 out of 400 planned patients), and harbored trial deficiencies likely to trigger an FDA rejection.
  • Stock Impact: When negative regulatory updates and realities regarding the BLA came to light, Replimune’s share price dropped significantly, causing substantial investor losses.

Attn add for free case evaluation in Replimune Class Action Lawsuit

What Is Securities Fraud?